Janssen Biotech Inc.

05/05/2024 | Press release | Distributed by Public on 05/06/2024 01:29

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively